Acceleration  ||| S:0 E:13 ||| NN
of  ||| S:13 E:16 ||| IN
keratinocyte  ||| S:16 E:29 ||| JJ
differentiation  ||| S:29 E:45 ||| NN
by  ||| S:45 E:48 ||| IN
transient  ||| S:48 E:58 ||| JJ
receptor  ||| S:58 E:67 ||| NN
potential  ||| S:67 E:77 ||| JJ
vanilloid  ||| S:77 E:87 ||| NNS
( ||| S:87 E:88 ||| -LRB-
TRPV6 ||| S:88 E:93 ||| NNP
)  ||| S:93 E:95 ||| -RRB-
channel  ||| S:95 E:103 ||| VBP
activation  ||| S:103 E:114 ||| JJ
Numerous  ||| S:114 E:123 ||| JJ
studies  ||| S:123 E:131 ||| NNS
have  ||| S:131 E:136 ||| VBP
demonstrated  ||| S:136 E:149 ||| VBN
the  ||| S:149 E:153 ||| DT
beneficial  ||| S:153 E:164 ||| JJ
effect  ||| S:164 E:171 ||| NN
of  ||| S:171 E:174 ||| IN
Avène  ||| S:174 E:180 ||| NNP
Thermal  ||| S:180 E:188 ||| NNP
Spring  ||| S:188 E:195 ||| NNP
Water  ||| S:195 E:201 ||| NNP
( ||| S:201 E:202 ||| -LRB-
TSW ||| S:202 E:205 ||| NNP
)  ||| S:205 E:207 ||| -RRB-
in  ||| S:207 E:210 ||| IN
dermatological  ||| S:210 E:225 ||| JJ
diseases  ||| S:225 E:234 ||| NNS
but  ||| S:234 E:238 ||| CC
the  ||| S:238 E:242 ||| DT
molecular  ||| S:242 E:252 ||| JJ
mechanisms  ||| S:252 E:263 ||| NNS
remain  ||| S:263 E:270 ||| VBP
unknown ||| S:270 E:277 ||| JJ
.  ||| S:277 E:279 ||| .
The  ||| S:279 E:283 ||| DT
objective  ||| S:283 E:293 ||| NN
of  ||| S:293 E:296 ||| IN
the  ||| S:296 E:300 ||| DT
present  ||| S:300 E:308 ||| JJ
study  ||| S:308 E:314 ||| NN
was  ||| S:314 E:318 ||| VBD
to  ||| S:318 E:321 ||| TO
evaluate  ||| S:321 E:330 ||| VB
the  ||| S:330 E:334 ||| DT
effect  ||| S:334 E:341 ||| NN
of  ||| S:341 E:344 ||| IN
Avène  ||| S:344 E:350 ||| NNP
TSW  ||| S:350 E:354 ||| NNP
on  ||| S:354 E:357 ||| IN
the  ||| S:357 E:361 ||| DT
morphological  ||| S:361 E:375 ||| NN
and  ||| S:375 E:379 ||| CC
molecular  ||| S:379 E:389 ||| JJ
features  ||| S:389 E:398 ||| NNS
related  ||| S:398 E:406 ||| VBN
to  ||| S:406 E:409 ||| TO
the  ||| S:409 E:413 ||| DT
more  ||| S:413 E:418 ||| RBR
advanced  ||| S:418 E:427 ||| JJ
status  ||| S:427 E:434 ||| NN
of  ||| S:434 E:437 ||| IN
differentiation  ||| S:437 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
human  ||| S:456 E:462 ||| JJ
keratinocytes ||| S:462 E:475 ||| NN
.  ||| S:475 E:477 ||| .
Normal  ||| S:477 E:484 ||| JJ
human  ||| S:484 E:490 ||| JJ
keratinocytes  ||| S:490 E:504 ||| NNS
( ||| S:504 E:505 ||| -LRB-
NHK ||| S:505 E:508 ||| NNP
)  ||| S:508 E:510 ||| -RRB-
were  ||| S:510 E:515 ||| VBD
differentiated  ||| S:515 E:530 ||| VBN
in  ||| S:530 E:533 ||| IN
medium  ||| S:533 E:540 ||| JJ
powder  ||| S:540 E:547 ||| NN
reconstituted  ||| S:547 E:561 ||| NN
with  ||| S:561 E:566 ||| IN
Avène  ||| S:566 E:572 ||| NNP
TSW  ||| S:572 E:576 ||| NNP
and  ||| S:576 E:580 ||| CC
assessed  ||| S:580 E:589 ||| VBN
by  ||| S:589 E:592 ||| IN
RT-PCR  ||| S:592 E:599 ||| JJ
and  ||| S:599 E:603 ||| CC
immunohistochemistry ||| S:603 E:623 ||| NN
.  ||| S:623 E:625 ||| .
Calcium  ||| S:625 E:633 ||| JJ
entry  ||| S:633 E:639 ||| NN
was  ||| S:639 E:643 ||| VBD
measured  ||| S:643 E:652 ||| VBN
by  ||| S:652 E:655 ||| IN
a  ||| S:655 E:657 ||| DT
Fura-2  ||| S:657 E:664 ||| NNP
AM  ||| S:664 E:667 ||| NNP
probe ||| S:667 E:672 ||| NN
.  ||| S:672 E:674 ||| .
TRPV6  ||| S:674 E:680 ||| NNP
channel  ||| S:680 E:688 ||| NN
were  ||| S:688 E:693 ||| VBD
detected  ||| S:693 E:702 ||| VBN
by  ||| S:702 E:705 ||| IN
immunohistochemistry ||| S:705 E:725 ||| NN
,  ||| S:725 E:727 ||| ,
RT-PCR  ||| S:727 E:734 ||| JJ
and  ||| S:734 E:738 ||| CC
western  ||| S:738 E:746 ||| JJ
blot ||| S:746 E:750 ||| NN
.  ||| S:750 E:752 ||| .
Treatment  ||| S:752 E:762 ||| NN
of  ||| S:762 E:765 ||| IN
NHK  ||| S:765 E:769 ||| NNP
with  ||| S:769 E:774 ||| IN
Avène  ||| S:774 E:780 ||| NNP
TSW  ||| S:780 E:784 ||| NNP
led  ||| S:784 E:788 ||| VBD
to  ||| S:788 E:791 ||| TO
an  ||| S:791 E:794 ||| DT
enhanced  ||| S:794 E:803 ||| JJ
constitutive  ||| S:803 E:816 ||| JJ
calcium  ||| S:816 E:824 ||| NN
entry  ||| S:824 E:830 ||| NN
that  ||| S:830 E:835 ||| WDT
resulted  ||| S:835 E:844 ||| VBD
in  ||| S:844 E:847 ||| IN
the  ||| S:847 E:851 ||| DT
increased  ||| S:851 E:861 ||| JJ
expression  ||| S:861 E:872 ||| NN
of  ||| S:872 E:875 ||| IN
involucrin  ||| S:875 E:886 ||| NN
and  ||| S:886 E:890 ||| CC
cytokeratins  ||| S:890 E:903 ||| CD
1  ||| S:903 E:905 ||| CD
and  ||| S:905 E:909 ||| CC
10 ||| S:909 E:911 ||| CD
.  ||| S:911 E:913 ||| .
This  ||| S:913 E:918 ||| DT
enhanced  ||| S:918 E:927 ||| JJ
constitutive  ||| S:927 E:940 ||| JJ
calcium  ||| S:940 E:948 ||| NN
entry  ||| S:948 E:954 ||| NN
in  ||| S:954 E:957 ||| IN
Avène  ||| S:957 E:963 ||| NNP
TSW-treated  ||| S:963 E:975 ||| JJ
keratinocytes  ||| S:975 E:989 ||| NN
was  ||| S:989 E:993 ||| VBD
mediated  ||| S:993 E:1002 ||| VBN
by  ||| S:1002 E:1005 ||| IN
the  ||| S:1005 E:1009 ||| DT
TRPV6  ||| S:1009 E:1015 ||| JJ
calcium  ||| S:1015 E:1023 ||| NN
channel ||| S:1023 E:1030 ||| NN
.  ||| S:1030 E:1032 ||| .
Moreover ||| S:1032 E:1040 ||| RB
,  ||| S:1040 E:1042 ||| ,
Avène  ||| S:1042 E:1048 ||| NNP
TSW-mediated  ||| S:1048 E:1061 ||| JJ
calcium  ||| S:1061 E:1069 ||| NN
entry  ||| S:1069 E:1075 ||| NN
was  ||| S:1075 E:1079 ||| VBD
due  ||| S:1079 E:1083 ||| JJ
to  ||| S:1083 E:1086 ||| TO
the  ||| S:1086 E:1090 ||| DT
increase  ||| S:1090 E:1099 ||| NN
in  ||| S:1099 E:1102 ||| IN
TRPV6  ||| S:1102 E:1108 ||| CD
expression  ||| S:1108 E:1119 ||| NN
as  ||| S:1119 E:1122 ||| IN
well  ||| S:1122 E:1127 ||| RB
as  ||| S:1127 E:1130 ||| IN
the  ||| S:1130 E:1134 ||| DT
channel  ||| S:1134 E:1142 ||| NN
abundance  ||| S:1142 E:1152 ||| NN
at  ||| S:1152 E:1155 ||| IN
the  ||| S:1155 E:1159 ||| DT
cell  ||| S:1159 E:1164 ||| NN
membrane ||| S:1164 E:1172 ||| NN
.  ||| S:1172 E:1174 ||| .
An  ||| S:1174 E:1177 ||| DT
other  ||| S:1177 E:1183 ||| JJ
mechanism  ||| S:1183 E:1193 ||| NN
of  ||| S:1193 E:1196 ||| IN
action  ||| S:1196 E:1203 ||| NN
of  ||| S:1203 E:1206 ||| IN
Avène  ||| S:1206 E:1212 ||| NNP
TSW  ||| S:1212 E:1216 ||| NNP
is  ||| S:1216 E:1219 ||| VBZ
described ||| S:1219 E:1228 ||| VBN
.  ||| S:1228 E:1230 ||| .
Avène  ||| S:1230 E:1236 ||| NNP
TSW  ||| S:1236 E:1240 ||| NNP
treatment  ||| S:1240 E:1250 ||| NN
induced  ||| S:1250 E:1258 ||| VBD
an  ||| S:1258 E:1261 ||| DT
enhanced  ||| S:1261 E:1270 ||| JJ
constitutive  ||| S:1270 E:1283 ||| JJ
calcium  ||| S:1283 E:1291 ||| NN
entry  ||| S:1291 E:1297 ||| NN
mediated  ||| S:1297 E:1306 ||| NN
by  ||| S:1306 E:1309 ||| IN
TRPV6  ||| S:1309 E:1315 ||| CD
channel  ||| S:1315 E:1323 ||| NN
leading  ||| S:1323 E:1331 ||| VBG
to  ||| S:1331 E:1334 ||| TO
the  ||| S:1334 E:1338 ||| DT
acceleration  ||| S:1338 E:1351 ||| NN
of  ||| S:1351 E:1354 ||| IN
human  ||| S:1354 E:1360 ||| JJ
keratinocytes  ||| S:1360 E:1374 ||| JJ
differentiation ||| S:1374 E:1389 ||| NN
.  ||| S:1389 E:1391 ||| .
